SightGlass Vision study shows myopia management effect in six and seven year olds

Results from a clinical trial using SightGlass Vision Diffusion Optics Technology has indicated the spectacle lens reduces myopia progression in six and seven-year-old children.

The findings follow analysis of 24-month interim data from the Cypress clinical trial.

Spectacle lenses, including the SightGlass Vision Diffusion Optics Technology, which utilises thousands of micro-dots that scatter light to reduce contrast on the retina, were shown to reduce axial length (mean absolute reduction of 0.27mm) and cycloplegic spherical equivalent refraction (SER) progression (mean absolute reduction of 0.77D) in six and seven-year-old children, compared to a control.

Held across 14 sites in the US and Canada, researchers randomised and dispensed lenses to 256 eligible children between six and 10 years old with myopia between -0.75D and -4.50D.

Nearly a third of participants were between six and seven years old and the mean age of participants was 8.1 years at the time of screening. Researchers noted that this made the cohort younger than children in many other myopia management studies.

Discussing the focus on age and the importance of the findings, Andrew Sedgwick, CEO of SightGlass Vision, said: “Young myopes can be difficult to manage for many reasons. Parents and eye care professionals have traditionally had a limited number of myopia control solutions for younger children.”

“Our latest analysis suggests that spectacles enabled with SightGlass Vision Diffusion Optics Technology offer a promising new approach to myopia control for six and seven-year-olds,” he added.

Two year effectiveness of a novel myopia management spectacle lens in young myopes (Rappon J, Neitz M, Chalberg T) will be presented at the 2022 Dutch Contact Lens Congress next week in The Netherlands. The trial is now in its third year.